Analyst consensus rating
Immunovant Analyst Rating: Buy
Direct answer
Immunovant's consensus rating is Buy.
16 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $48.88.
Forecast evidence checked October 17, 2026.
Get free Immunovant email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $26.73
- Average price target
- $48.88
- High price target
- $66.00
- Low price target
- $30.00
- Low target gap
- +12.2%
- Target upside
- +82.8%
- High target gap
- +146.9%
- Target range width
- 134.7%
- Consensus rating
- Buy
- Analysts
- 16
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Immunovant?
Immunovant has a verified Buy consensus. The same dataset has an average price target of $48.88.
How far are Immunovant's low and high targets from the recorded price?
The low target implies +12.2%, while the high target implies +146.9%.
How many analysts are included in Immunovant's consensus?
The verified consensus includes 16 analysts.
How is Immunovant's target upside or downside calculated?
The average target of $48.88 is divided by the recorded price of $26.73, then one is subtracted to produce +82.8%. This does not guarantee a future return.
When was Immunovant's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.